NFE2L2 and cancer: Targeting this regulatory axis—either by direct inhibition of Nrf2 or through blockade of its upstream activators and downstream effectors—offers a compelling opportunity to disrupt redox homeostasis and re-sensitize cancer cells to ferroptosis-inducing agents.